NatiVita

en
  • Русский
  • English

Press releases

13.02.2019
NatiVita will produce the vaccine for the treatment of lung cancer

CEO JLLC NATIVITA Republic of Belarus and CIM S.A. (CENTRO DE INMUNOLOGIA MOLECULAR) Republic of Cuba with the support of the Embassy of the Republic of Belarus in the Republic of Cuba and participation of BioCubaFarma entered into a treaty on the transfer technology of full cycle production and quality control of the vaccine CIMAvax-EGF.

More
1.02.2019
Vuln!! Path it now!!

Vuln!! Path it now!!

Vuln!! Path it now!!<br />

More
26.12.2018
NatiVita Academic Board selected the best project in biotechnology in the innovational projects contest

On December 26th the results of the 9th National Contest of Innovational projects were announced in Minsk where they named a winner of the special nomination by NatiVita called “Biotechnology and genomics in medicine and pharmaceuticals”.

More
20.11.2018
TALENAVITA: year in review and awarding of the best participants

On November 17th the final event of TALENAVITA 2018 took place in Vitebsk. More than 500 best students and senior school children from all over Belarus took part in it.

More
19.11.2018
NatiVita registered Hepcinat drug

NatiVita received a registration certificate for Hepcinat drug – it’s the second drug for virus hepatitis C treatment in the product portfolio of the company.

More
16.11.2018
The best students and senior school pupils of TALENAVITA project will be awarded on Students’ day in Vitebsk

More than 500 best students and senior school children from all over Belarus will be awarded by legendary sportsmen and scientists at the final event of TALENAVITA program on November 17th in Vitebsk.

More
2.10.2018
NatiVita has registered drugs in Moldova

NatiVita has registered the first medicinal products in the Republic of Moldova.

More